SCHEMBL5148618

SCHEMBL5148618

CCCn1ncc(CN)c1NC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 2/20 0.35
KIF11 P52732 1/20 0.33
BPTF Q12830 1/20 0.31
KAT2B Q92831 1/20 0.31
SLC9A1 P19634 1/20 0.31
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5148607 0.89 KCNN4 (0.37) KCNN4KIF11BPTF
SCHEMBL5148612 0.78 ALDH1A1 (0.36) KCNN4POLB
SCHEMBL5148583 0.77 CKS1B (0.37) POLB
SCHEMBL5147620 0.71 KIF11 (0.36) KCNN4KIF11BPTFKAT2B
SCHEMBL6065937 0.70 GAA (0.35) KCNN4KIF11
SCHEMBL28760707 0.68 MEN1 (0.35)
SCHEMBL6065935 0.68 GAA (0.35) KCNN4
SCHEMBL5151955 0.67 DRD2 (0.39)
SCHEMBL3113554 0.67 KCNN4 (0.37) KCNN4KIF11BPTFKAT2B
SCHEMBL3116816 0.67 GAA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179801-B2 Cephem compounds ASTELLAS PHARMA INC. (JP) 2007-02-20 US disclosed
EP-1392704-B1 CEPHEM COMPOUNDS ASTELLAS PHARMA INC (JP) 2006-02-22 EP disclosed
US-20040248875-A1 Cephem compounds ASTELLAS PHARMA INC. (JP) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248875-A1 Cephem compounds CEP170, C1S, SLC7A1 KCNN4 3410/4885KIF11 3495/4885BPTF 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.